Carfilzomib

Multiple Myeloma Treatment

Carfilzomib is used to treat adults with multiple myeloma. This is a cancer of the plasma cells, which are white blood cells that help the body fight infection. It is specifically indicated for patients with relapsed or refractory disease, meaning the cancer has come back after treatment or did not respond to initial therapies.

Combination Therapy

This medication is often used in combination with other drugs to improve its effectiveness. Common combination treatments include:

• Dexamethasone
• Lenalidomide and dexamethasone
• Daratumumab and dexamethasone
• Isatuximab and dexamethasone

Single-Agent Use

In some cases, carfilzomib may be used alone. This typically occurs in patients who have already tried at least two other types of treatment, including a proteasome inhibitor and an immunomodulatory agent, but whose cancer has continued to progress.

Mechanism of Action

Carfilzomib belongs to a class of medications known as proteasome inhibitors. It is used to treat certain types of cancer, such as multiple myeloma, by interfering with the way cells handle proteins.

Every cell contains enzyme complexes called proteasomes. These act as a disposal system that breaks down and recycles proteins the cell no longer needs. Carfilzomib works by binding to these proteasomes and preventing them from functioning.

When proteasomes are blocked, the following occurs:

• Protein Buildup: Proteins that should be destroyed begin to accumulate inside the cell.
• Cellular Stress: This buildup creates a toxic environment that disrupts the cell's normal functions.
• Cell Death: The internal stress eventually triggers a process called apoptosis, or programmed cell death.

Cancer cells, particularly multiple myeloma cells, are often more sensitive to this process than healthy cells. This is because cancer cells grow quickly and produce proteins at a much higher rate, making them more dependent on the proteasome system to stay alive. By targeting this system, carfilzomib helps to reduce the number of cancer cells in the body.

Common Side Effects

Many people receiving carfilzomib experience mild to moderate side effects. These may include:

• Tiredness or weakness
• Nausea, vomiting, or diarrhea
• Fever and chills
• Headache
• Cough and shortness of breath
• Swelling in the hands, feet, or ankles
• Muscle or joint pain
• Low blood cell counts, which may increase the risk of infection, bruising, or anemia

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact your healthcare provider right away if you experience:

• Heart problems: New or worsening shortness of breath, chest pain, or a fast or irregular heartbeat.
• Kidney issues: Changes in urination, swelling, or blood in the urine.
• Lung complications: Severe difficulty breathing or a sudden cough.
• Infusion reactions: Fever, chills, dizziness, or flushing during or shortly after the treatment.
• Liver toxicity: Yellowing of the skin or eyes, dark urine, or pain in the upper right stomach area.
• Blood clots: Pain, swelling, or warmth in a leg or arm, or sudden chest pain.
• Tumor Lysis Syndrome: A condition caused by the fast breakdown of cancer cells, which can lead to kidney failure or heart rhythm changes.
• Neurological issues: Seizures, confusion, or vision changes.

Cardiac and Respiratory Risks

Serious and sometimes fatal heart problems have occurred, including heart failure and heart attacks. Patients with pre-existing heart conditions may be at higher risk. Additionally, lung-related issues such as pulmonary hypertension and acute respiratory distress syndrome have been reported.

Kidney and Liver Function

Acute kidney failure and liver toxicity, including liver failure, are potential risks. Healthcare providers typically monitor kidney and liver function through regular blood tests throughout the course of treatment.

Infusion-Related Reactions

Infusion reactions can occur during or within 24 hours of administration. Symptoms may include:

• Fever and chills
• Joint or muscle pain
• Flushing or swelling of the face
• Vomiting or weakness
• Shortness of breath or chest tightness
• Fainting or low blood pressure

Tumor Lysis Syndrome (TLS)

TLS is a condition caused by the rapid breakdown of cancer cells, which releases toxins into the bloodstream. This can lead to kidney failure or abnormal heart rhythms. Maintaining adequate hydration before and during treatment is a common preventive measure.

Blood and Neurological Disorders

Carfilzomib may cause a significant drop in platelet counts (thrombocytopenia), increasing the risk of bruising or bleeding. Rare but serious neurological conditions, such as Posterior Reversible Encephalopathy Syndrome (PRES), and blood-clotting issues like Thrombotic Microangiopathy (TMA) have also been documented.

Hypertension

High blood pressure, including hypertensive crisis, has been observed in patients receiving this medication. Blood pressure should be monitored regularly, and treatment may need to be adjusted if hypertension develops.

Pregnancy and Reproduction

This drug can cause harm to a developing fetus. Effective contraception should be used by females of reproductive potential and by males with female partners of reproductive potential during treatment and for a specified period after the final dose.

Pregnancy

Carfilzomib can cause harm to a developing fetus. It is generally recommended that individuals avoid becoming pregnant while receiving this medication. Healthcare providers typically perform a pregnancy test before starting treatment to ensure the patient is not pregnant.

Contraception Requirements

• Females: Those who can become pregnant should use effective contraception during treatment and for 6 months after the final dose.
• Males: Those with female partners who can become pregnant should use effective contraception during treatment and for 3 months after the final dose.

Breastfeeding

It is currently unknown if carfilzomib passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 2 weeks following the last dose.

Fertility

Treatment with carfilzomib may affect fertility in both men and women. This may impact the ability to conceive a child in the future. Patients should discuss these risks with their healthcare team before starting treatment.

Dosage Forms

Carfilzomib is supplied in the following form:

• Lyophilized Powder for Injection: This is a sterile, white to off-white freeze-dried cake or powder provided in a single-dose vial.

This medication does not contain any antimicrobial preservatives. It must be reconstituted with sterile water for injection and then further diluted into an intravenous bag before it is administered into a vein. It is not available in oral forms such as tablets or capsules.

FDA Approval Status

Carfilzomib was initially granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2012. It is currently approved for the treatment of patients with relapsed or refractory multiple myeloma who have already received other forms of therapy.

Approved Indications

The FDA has approved carfilzomib for use in several specific clinical scenarios:

• Monotherapy: As a single agent for patients who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and whose disease progressed during or shortly after their last treatment.
• Combination Therapy: In combination with dexamethasone, or with lenalidomide and dexamethasone, for patients who have received one to three prior lines of therapy.
• Combination with Monoclonal Antibodies: In combination with daratumumab and dexamethasone, or with isatuximab and dexamethasone, for patients who have received one to three prior lines of therapy.

Regulatory Requirements

Carfilzomib is a prescription-only medication administered as an intravenous injection by healthcare professionals. While it does not carry a boxed warning, the FDA-approved labeling includes significant warnings regarding the risk of heart failure, lung complications, and kidney toxicity. There is no Risk Evaluation and Mitigation Strategy (REMS) program currently required for this medication, but it is subject to ongoing safety monitoring by the FDA.

Carfilzomib is an intravenous medication administered by healthcare professionals in a clinical setting, such as a hospital or infusion center. Because it is not a drug purchased at a retail pharmacy, the total cost typically includes the price of the medication along with facility fees and professional administration charges.

Factors Affecting Cost

Several factors can influence the overall expense of carfilzomib therapy:

• Dosage and Frequency: The dose is often calculated based on a patient's body surface area. More frequent administration or higher doses will increase the total cost.
• Combination Therapy: Carfilzomib is frequently used in combination with other medications, such as dexamethasone or daratumumab, which adds to the total cost of the treatment regimen.
• Insurance Coverage: Most insurance plans cover carfilzomib under medical benefits rather than pharmacy benefits. Out-of-pocket costs like deductibles, co-insurance, and co-payments will vary by plan.

Financial Assistance

Patients may be able to reduce their out-of-pocket expenses through various programs:

• Manufacturer Assistance: Some pharmaceutical companies offer co-pay cards or patient assistance programs for those who meet specific eligibility criteria.
• Support Organizations: Non-profit organizations may provide grants or financial aid to help patients with the costs of cancer treatment.